Advanced science (Weinheim, Baden-Wurttemberg, Germany)
KRAS Withdrawal in Cholangiocarcinoma Leads to Immune Infiltration and Tumor Regression.
Youwei Qiao, Matthew F Yee, Chaitanya N Parikh, Boyang Ma, Yueying Cao, Yu-Huan Shih, Joae Qiong Wu, Marcus Ruscetti, Shun-Qing Liang, Wen Xue
Published: 202510.1002/advs.202511312
Abstract
Cholangiocarcinoma (CCA) is a liver cancer subtype with poor survival rates. KRAS mutations are found in 15-40% of CCA, representing a new potential treatment target. Whether KRAS inhibition leads to CCA tumor regression is unknown, partly due to the…
Preview only. Read the full abstract at the source